William Blair & Company
VERV

William Blair & Company’s Verve Therapeutics VERV Stock Holding History

William Blair & Company’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,875
Closed -$229K – 2024
2021
Q3 		$229K Sell
4,875
-30,725
-86% -$1.81M ﹤0.01% 1432
2021
Q2 		$2.15M Buy
+35,600
New +$1.48M 0.01% 690

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company's VERV Position: Q4 2021 in Review

William Blair & Company sold out of Verve Therapeutics (VERV) in Q4 2021, closing a stake of 4,875 shares — an estimated $229K sold.

William Blair & Company first reported a position in VERV in Q2 2021 and held it in 2 quarters. The position peaked at $2.15M in Q2 2021. 96 funds tracked by Wall St. Rank hold VERV as of Q4 2021.

  • William Blair & Company reported no remaining Verve Therapeutics position as of Q4 2021 after selling out during the quarter.
  • William Blair & Company sold 4,875 Verve Therapeutics shares in Q4 2021, an estimated $229K.
  • William Blair & Company first reported a position in Verve Therapeutics in Q2 2021 and held it in 2 quarters.
  • William Blair & Company's Verve Therapeutics position peaked at $2.15M in Q2 2021.
  • 96 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2021.

Based on William Blair & Company's 13F filing for Q4 2021, filed 14 Feb 2022.